



38th Annual Medical & Scientific Conference

CVD – How important are lipids?

Monday 7 - Thursday 10 July 2025 | University of Warwick (Coventry)

Programme

This conference is endorsed by:



CPD: This conference has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 14 category 1 (external) CPD credit(s).

Monday 7 July

Time	Session duration		Topic	Venue location
11:00 - 13:00	90	Invited participants only CPD not applicable	HEART UK Board meeting Chaired by: Jules Payne + Dr Pete Green	Radcliffe - space 12
13:00 - 14:00	60		HEART UK lunch for Board members Hosted by: Jules Payne	Radcliffe lounge area - ground floor (raised area by the bar)
14:00 - 15:00	120	Invited participants only CPD not applicable	HEART UK Board member training Hosted by: Jules Payne	Radcliffe- space 12
15:30 - 17:00	120	Invited participants only CPD not applicable	HEART UK strategy discussions Hosted by: Jules Payne	Radcliffe- space 12
18:00 - 22:00	240		Expo build	Oculus foyer
18:45 - 19:15			HEART UK - meet the team Hosted by: Jules Payne	Radcliffe lounge area - ground floor (raised area by the bar)
19:30			HEART UK + informal speaker dinner Hosted by: Jules Payne	Radcliffe private dining room 2 (by bar)

Tuesday 8 July

Time	Session duration		Topic	Speaker	Venue location
07:00 - 09:00			Breakfast (<i>Bluebell House residential guests only</i>)		Rootes Building - 1st floor restaurant
08:00 - 09:30	90	Invited participants only CPD not applicable	HEART UK MS&R Committee meeting Chaired by: Prof Handrean Soran		Oculus 1.01 - 1st floor
08:30			Registration opens		Oculus foyer
09:30 - 10:45			Refreshments Networking Exhibition		Oculus foyer
09:30 - 10:30	60	Invited participants only CPD not applicable	Lipid Interest group meeting Chaired by: Ms Alison Pottle		Oculus 1.09 - 1st floor

10:30 - 10:45			Comfort break	
10:45 - 11:50	65	Livestream	SESSION 1 Welcome + Lipids - the big picture	Oculus LT 1.05 - 1st floor
10:45 - 10:50	5	Livestream	Chairman's Welcome Dr Peter Green (Chair, HEART UK)	
			Co-chairs: Prof Dev Datta + Ms Michaela Nuttall	
10:50 - 11:15	25	Livestream	Plenary speaker CVD – in the current landscape how important are lipids? Highlighting where lipids fit within CVD Prevention in England and how we are currently performing on key indicators. Dr Helen Williams (National clinical director for cardiovascular disease prevention, NHS England, London, UK)	
11:15 - 11:40	25	Livestream	Plenary speaker Cholesterol and the brain LDL cholesterol lowering is a key element of effective primary and secondary prevention of stroke but is under recognized and poorly implemented. Prof Gary Ford (Professor of Stroke Medicine, University of Oxford, UK)	
11:40 - 11:50	10		Group discussion	
11:50 - 12:30	40		Lunch	Oculus foyer
11:50 - 12:30	40	Grab a lunch and join sessions (in person only)	Chemical Pathology trainee networking forum Hosted by: Dr Andreas Tridimas Calling all Chem path trainees and SpR - Pick up a grab and go lunch and join our new forum for an informal discussion. Oculus - 0.02 grnd floor	UK Paediatric FH Alliance The UK Paediatric FH Alliance lunchtime session offers a great opportunity for paediatric healthcare professionals to connect, share experiences, and receive clinical support and advice in a relaxed, networking-friendly environment. Hosted by: Ms Lorraine Priestley-Barnham Oculus - 1.09 first floor
12:30 - 13:30	60	Livestream	SESSION 2 BACPR joint session	Oculus LT 1.05 - 1st floor
			Organised by: Jules Payne + BACPR	
			Co-chaired by: Dr Tina Khan + Ms Lisa Gritzmacher	
12:30 - 12:55	25	Livestream	Plenary speaker Cardiovascular Rehabilitation: Strengthening Hearts, Reducing Risks Ms Heather Probert (Consultant Physiotherapist / Cardiovascular Prevention & Rehabilitation Lead, Harefield and Royal Brompton Hospitals, London, UK)	
12:55 - 13:20	25	Livestream	Plenary speaker Impact of cardiovascular rehabilitation Cardiovascular Rehabilitation is an evidenced based programme delivered international, yet despite extensive research, routine care is varied and service variation can impact on successful pathway and patient outcomes. Dr Alex Harrison (Research Fellow/Lead Analyst, University of York, UK)	
13:20 - 13:30	10		Group discussion	
13:30 - 14:00	30		Refreshments Networking Exhibition	Oculus foyer
14:00 - 15:00	60	Livestream	SESSION 3 Diet and lifestyle - myth busting	Oculus LT 1.05 - 1st floor
			Organised by: Ms Lynne Garton	
			Co-Chairs: Ms Lynne Garton + Mr Alan Flanagan	
14:00 - 14:25	25	Livestream	Plenary speaker Effective weight management advice for CVD prevention This session will look at different nutritional strategies for weight management in those patients with CVD and consider the practicalities of such advice. Dr Tom Butler (Senior Lecturer in Nutrition and Health, Edgehill University, Ormskirk, UK)	

14:25 - 14:50	25	Livestream	Plenary speaker Dietary management in type 2 diabetes – from prevention to remission This talk will cover the dietary management of people living with type 2 diabetes from prevention to remission, with focus on the evidence base and telling fact from fiction. Dr Adrian Brown (NIHR Advanced Fellow and Senior Research Fellow; Senior Specialist Dietitian, University College London, UK)	
15:30 - 16:10	40	 Livestream	Symposia session 1 Recent Advances in Homozygous Familial Hypercholesterolemia Management This session highlights the burden of Homozygous Familial Hypercholesterolemia through the lived experience of a patient and presents the latest management strategies. Chair: Prof. Dev Datta Evkeeza ▼ (evinacumab) Clinical Efficacy, Safety, and Tolerability Data Prof. Dev Datta UK Real-World Experience with Evkeeza (evinacumab) Dr. Tina Khan Lived Experience of a Patient with Homozygous Familial Hypercholesterolemia Ms. Alison Pottle + Patient Ambassador Q&A Sponsored by Ultragenyx Date of preparation: April 2025 Job code: UK-MRCP-UX858-00833 Adverse events should be reported. Reporting forms and information can be found at (UK): https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to ultragenyx@primevigilance.com or +44 (0)203 1399039.  <i>Sponsored symposia sessions are not CPD accredited directly by HEART UK. This symposium is intended for UK healthcare professionals only. This promotional meeting has been organised and funded by Ultragenyx.</i>	
16:10:00			Changeover	
16:10 - 16:50	40	 Livestream	Symposia session 2 Programme development by sponsor Sponsored by Sanofi <i>Sponsored symposia sessions are not CPD accredited directly by HEART UK. This symposium is intended for UK healthcare professionals only. This symposium is organised and funded by Sanofi.</i>	Oculus LT 1.05 - 1st floor
16:50 - 17:50	60	Livestream	SESSION 5 Obesity Organised and co- chaired by: Prof Dev Datta and Prof Handrean Soran	Oculus LT 1.05 - 1st floor

16:50 - 17:10	20		Plenary speaker Incretin therapies for weight loss This talk will cover the history, development and latest news for incretin therapies based on GLP-1, GIP and allied hormones Prof Tricia Tan (Chair in Metabolic Medicine and Endocrinology, Imperial College, London, UK)	
17:10 - 17:30	20		Plenary speaker Treatment of obesity in people with cardiovascular disease Presentation of best available data regarding the impact of the treatment of obesity in people with cardiovascular disease. Prof Alex Miras (Professor of Endocrinology, Ulster University, Derry, UK)	
17:30 - 17:50	20		Panel discussion	
17:50 - 18:00			Comfort break	
18:00 - 18:50	50	In person only	FH and allied health professional networking session This is a networking session where FH nurses and allied health care professionals working with familial hypercholesterolaemia can meet and share best practice, information on current projects (national or local) or ask for advice about any issues or barriers they are experiencing in their work. We are a supportive group and welcome all newcomers to the field of FH work. Hosted by: Ms Lisa Gritzmacher <i>CPD is not applicable to this session</i>	Oculus - 0.02 grnd floor
18:50 - 19:50	60	In person only	Spotlight on posters - meet the authors An informal session where the audience can meet all the poster authors to discuss their work. This session is unjudged. <i>See poster listing at end of programme</i>	Oculus - 1st floor landing
19:00 - 21:30	60		Welcome and buffet reception	Oculus foyer
19:30:00			Chairman's welcome Dr Pete Green Premium sponsor welcome Presentation of the Rianna Wingett award	
21:30:00			Evening ends	



Wednesday 9 July

Time	Session duration		Topic	Speaker	Venue location
07:00 - 09:00			Breakfast (<i>Bluebell House residential guests only</i>)		Rootes Building - 1st floor restaurant
08:00 - 08:45					Radcliffe tbc
08:00 - 09:00	60	Invited participants only CPD not applicable	Healthcare committee meeting Chaired by: Ms Michaela Nuttall <i>Invited attendance only - CPD is not applicable</i>		Oculus 1.01 - 1st floor
08:30			Registration opens		Oculus foyer
08:30 - 09:10	50		Refreshments Networking Exhibition		Oculus foyer
09:10 - 09:15	5		Opening remarks Prof Dev Datta		Oculus LT 1.05 - 1st floor
09:15 - 10:25		Livestream	SESSION 6 CVD and other considerations		Oculus LT 1.05 - 1st floor
			Organised by: Dr Tina Khan		
			Co-chairs: Dr Tina Khan + Dr Bilal Bashir		

			Plenary speaker Managing Ischaemic Cardiomyopathy – the sequelae of progressive cardiovascular disease Heart failure is one of the ultimate consequences of ischaemic heart disease, and the options for treating heart failure have significantly increased over recent years.	
09:15 - 09:35	20	Livestream	Dr Anthony Barron (Royal Brompton & Harefield Hospital, London, UK)	
09:35 - 09:45	10		Discussion	
			Plenary speaker Dementia and CVD (cover false news about link to statins) The relationship between dementia and cardiovascular disease is complex and often misunderstood, with widespread misinformation surrounding the alleged link between statins and cognitive decline.	
09:45 - 10:05	20	Livestream	Prof Manuela Casula (Assistant Professor, Department of Pharmacological and Biomolecular Sciences, University of Milan, ITALY)	
10:05 - 10:15	10		Discussion	
10:15 - 10:25	10		Panel discussion	
10:25 - 10:55	30		Refreshments Networking Exhibition	Oculus ground floor
	85	Livestream	SESSION 7 Paediatrics	Oculus LT 1.05 - 1st floor
10:55 - 11:05			Organised by: Ms Lorraine Priestley-Barnham	
			Co-chairs: Ms Lorraine Priestley-Barnham + Dr Nigel Capps	
			Plenary speaker Starting Strong: The Case for Early Atherosclerotic Cardiovascular Risk Assessment and Intervention in Paediatric Clinics Emerging challenges and opportunities in cardiovascular risk management in pediatrics.	
10:55 - 11:15	20	Livestream	Dr. H.S. (Henk) Schipper (Erasmus MC, Rotterdam, The Netherlands)	
			Plenary speaker Dyslipidaemias and Preclinical Atherosclerotic Cardiovascular Disease in Childhood Chronic Conditions: Preliminary Results from the SMART-Youth Study	
11:15 - 11:30	15	Livestream	Dr Isabelle van der Linden (Medical Researcher, University Medical Center Utrecht – Wilhelmina Children’s Hospital, Utrecht, The Netherlands)	
			Plenary speaker Factors Influencing Treatment Adherence in Childhood and Adolescence: A Psychological Perspective Understanding the ‘why’ behind treatment adherence behaviours amongst your paediatric patients to understand how to better support them to follow life-long dietary, physical activity and pharmacological treatment advice.	
11:30 - 11:50	20	Livestream	Dr Fiona Kinnear (Honorary Research Associate, The University of Bristol, UK)	
			Plenary speaker Dietary Counselling Strategies in the Paediatric Lipid Clinic, Supporting Children, Young People and their Families My experience as a paediatric dietitian working within our paediatric familial hypercholesterolaemia service.	
11:50 - 12:05	15		Miss Anna Bruce (Specialist Paediatric Metabolic Dietitian, Nottingham Children’s Hospital, UK)	
12:05 - 12:20	15		Discussion	
12:20 - 13:00	40	 Livestream	Symposia session 3 Programme development by sponsor Sponsored by Amgen <i>Sponsored symposia sessions are not CPD accredited directly by HEART UK. This Amgen sponsored symposium is intended for UK healthcare professionals only. This promotional symposium is organised and funded by Amgen.</i>	Oculus LT 1.05 - 1st floor
13:00 - 13:35	35		Lunch Networking Exhibition	Oculus ground floor
12:55 - 13:35	45	Invited participants only CPD not applicable	Simon Broome committee meeting Chaired by: Dr Nigel Capps	Oculus 1.01 - 1st floor
13:00 - 13:10	10	In person only	Premium sponsor "Meet the expert"	

13:05 - 13:35		Grab a lunch and join sessions (in person only)	Pharmacy update Organised by: Prof Peter Penson Oculus 0.02 - grnd floor <i>CPD is not applicable to this session</i>	HEART UK Early Career Cardiovascular Disease Prevention (ECCDP) Network Chaired by: Dr Bilal Bashir Oculus 1.09 - 1st floor <i>CPD is not applicable to this session</i>	
13:35 - 14:45	70	Livestream	SESSION 8 Women and CVD		Oculus LT 1.05 - 1st floor
			Organised and Chaired by: Dr Tina Khan + Prof Liz Hughes		
13:35 - 13:55	20	Livestream	Plenary speaker Cardiovascular risk management during puberty, conception, pregnancy and beyond Dr Antonio de Marvao (London, UK)		
13:55 - 14:05	10		Discussion		
14:05 - 14:25	20+10	Livestream	Plenary speaker The impact of Menopause on Lipids and the role of HRT Effect of oestrogen deficiency and replacement on lipids and lipoproteins Prof John Stevenson (Consultant Metabolic Physician, Royal Brompton Hospital, London, UK)		
14:25 - 14:35	10		Discussion		
14:35 - 14:45	10		Panel discussion		
14:45 - 15:20	35		Refreshments Networking Exhibition		Oculus foyer
15:20 - 16:35	75	Livestream	SESSION 9 Abstracts of free communications Group 1 Oculus LT 1.05 - 1st floor	SESSION 10 Abstracts of free communications Group 2 Oculus LT 0.03 - ground floor	
			Co-chairs: Ms Lorrain Priestley-Barnham + Dr Andreas Tridimas	Co-chairs: tbc	
15:20 - 15:30	10		FC 1 Polygenic predisposition to increased LDL-cholesterol concentration and Carotid Artery Intima Media Thickness in childhood and early adulthood Marta Futema (London, UK)	FC 6 Testosterone Undecanoate Significantly Reduces LDL-Cholesterol and Triglycerides in Men with Adult-Onset Testosterone Deficiency Anirudh Bhat (Birmingham, UK)	
15:30 - 15:35	5		Discussion	Discussion	
15:35 - 15:45	10		FC 2 Development of a diagnostic score to identify children with Familial Hypercholesterolaemia – The Familial Hypercholesterolemia Pediatric Diagnostic Score (FH-PeDS) Steve Humphries (London, UK)	FC 7 “Fear of missing out”: Does upfront combination therapy following acute coronary syndrome (ACS) significantly decrease subsequent eligibility for injectable lipid-lowering therapies? Jonathan Fenwick (Gateshead, UK)	
15:45 - 15:50	5		Discussion	Discussion	
15:50 - 16:00	10		FC 3 Apolipoprotein B/LDL-C discordance and lipoprotein(a) as predictors of ASCVD risk in genetically confirmed heterozygous familial hypercholesterolemia (HeFH): A Retrospective Cohort Study (2005–2023) Nader Genedy (Cardiff, UK)	FC 8 Clinical trial experience using in vivo base editing medicines for cardiovascular disease that aim to durably lower LDL cholesterol after a single treatment Scott Vafai (Boston, USA)	
16:00 - 16:05	5		Discussion	Discussion	
16:05 - 16:15	10		FC 4 Expanded Clinical Experience of Children with Homozygous Familial Hypercholesterolaemia (HoFH) Under 5 Years of Age Treated with Evinacumab Through Compassionate Use Programs Lay Ean Tan (Novato, USA)	FC 9 Chylomicronaemia secondary to GPIHBP1 autoantibodies giving rise to functional LPL deficiency: is this an under-recognised rare explanation for those with an otherwise unexplained secondary hypertriglyceridaemia? Nathan Cantley (Bristol, UK)	
16:15 - 16:20	5		Discussion	Discussion	

			FC 5 Genetic Diagnosis of Familial Hypercholesterolemia in Residual Newborn Dried Blood Spots Steve Humphries (London, UK)	FC 10 Hypertriglyceridemia and pancreatitis: Prevention success with older lipid lowering medication in a case with comorbidities Einaz Mohamed (London, UK)	
16:20 - 16:30	10				
16:30 - 16:35	5		Discussion	Discussion	
16:35 - 17:05	30		Refreshments Networking Exhibition		
	60	Livestream	SESSION 11 Myant lecture		
			Chair: Prof Handrean Soran		
17:05 - 18:05	60		Atherosclerosis: lipids, inflammation, the bone marrow, and beyond Prof Peter Libby (Cardiovascular Specialist, Brigham and Women's Hospital in Boston, USA)		
18:05 - 18:10	5		Day two closing remarks		
18:10	5		Annual conference 2025 - attendee group photo		
19:00 - 19:30			Pre dinner drinks reception		
19:30 - 23:30			Conference dinner A black tie affair		



Thursday 10 July

Time	Session duration		Topic	Speaker	Venue location
07:00 - 09:00			Breakfast (Bluebell House residential guests only)		
08:30			Registration opens		
08:00 - 09:00		Invited participants only CPD not applicable	Apheresis Working Group committee meeting Chaired by: Prof Dev Datta		
08:30 - 09:30	60		Refreshments Networking Exhibition		
08:50 - 09:50	60	In person only	Spotlight on posters session		
			Moderated only		
			Judges Tina Khan , Peter Penson , Andreas Tridimas		
			MP 01 - MP10		
		MP1	Real-world safety and effectiveness of lomitapide in homozygous familial hypercholesterolaemia over ten years: Data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER) Jai Cegla (London, UK)		
		MP2	Paediatric familial hypercholesterolaemia database at a single tertiary centre: a review of patients managed under the paediatric lipid clinic at Hammersmith Hospital Peter Chua (London, UK)		
		MP3	Efficacy of Evinacumab by Genotype and Low-density Lipoprotein Receptor Function in Patients with Homozygous Familial Hypercholesterolaemia: A Subanalysis from the ELIPSE Open-label Extension Study Ester Cotali (Novato, USA)		
		MP4	Lomitapide in paediatric patients with homozygous familial hypercholesterolaemia (HoFH) – Analysis of long-term (104-week) safety and efficacy from the APH-19 study Phil Dawson (Dublin, IRELAND)		

		MP5	Assessing Service quality for Homozygous Familial Hypercholesterolaemia (HoFH) in the UK: Insights from a Multi-Centre Survey Maryam Ferdousi (Manchester, UK)	
		MP6	Beyond LDL: Uncovering residual cardiovascular risk in familial hypercholesterolemia – the MATCH-FH cohort study Nader Genedy (Cardiff, UK)	
		MP7	Treatment of Familial Chylomicronaemia Syndrome with Lomitapide Nathan Lorde (Birmingham, UK)	
		MP8	Hypertriglyceridaemic Pancreatitis, Unmet Needs and How to Address: Preliminary Data from a National Project Atiqah Sapiyan (Manchester, UK)	
		MP9	Introduction of a new stroke lipid specialist nurse to improve lipid optimisation for acute ischaemic stroke patients Aravind Udayan (London, UK)	
		MP10	Ascertainment of Familial Hypercholesterolaemia in diverse primary care populations using the FAMCAT2 tool: Comparison of screening criteria and management in primary care Uma Walgama (London, UK)	
	50		SESSION 12 - Sponsored symposia	
10:00 - 10:40	40	 Symposia session 4 From Diet to Drug Therapy: An Integrated Approach to Liver Health in HoFH Join us as we examine an integrated approach to liver health in HoFH, spanning from dietary management to pharmacologic therapy with insights from real-world case studies. 10:00 – 10:15 Prof Handrean Soran, Consultant Physician and Endocrinologist – Manchester University NHS Foundation Trust (MFT)  10:15am – 10:35  Alison Pottle, Nurse Consultant - Harefield Hospital Kate Twine, Consultant Dietician  10:35 – 10:40  Q&A session This symposia session will not be livestreamed or be available on demand Sponsored by Chiesi Ltd <i>Sponsored symposia sessions are not CPD accredited directly by HEART UK. This Chiesi sponsored symposium is intended for UK healthcare professionals only. This promotional symposium is organised and funded by Chiesi.</i>		
10:40 - 10:50	10		Changeoever	
	40	 Symposia session 5 Sponsored by Daiichi Sankyo Medical Affairs <i>Sponsored symposia sessions are not CPD accredited directly by HEART UK. This symposium has been organised and funded by Daiichi Sankyo UK Ltd and is intended for GB HCPs only</i> Livestream	Oculus LT 1.05 - 1st floor	
11:30 - 11:50	20		Refreshments Networking Exhibition	Oculus foyer
11:50 - 12:50		Livestream	SESSION 13 Late breaking session	Oculus LT 1.05 - 1st floor
			Co-chairs: tbc	
11:50 - 12:10	20		UK Standards for Lipid Reporting Dr Julia Kenkre (Imperial College, London, UK)	
12:10 - 12:30	20		Hypertriglyceridaemia and cardiometabolic risk Prof Handrean Soran (Manchester, UK)	
12:30 - 12:50	20		Panel discussion	

12:50 - 14:20		Livestream	SESSION 14 Clinical Lipidology Live		Oculus LT 1.05 - 1st floor
12:50 - 14:0	70		Live patient case studies and discussion Facilitator: Prof Dev Datta Panel members:		
14:00 - 14:20	10		Presentation of prizes and awards Closing remarks Dr Pete Green (Chair - HEART UK)		
14:20:00			Conference close		
			Unmoderated posters		
			Networking session Tues 8 July 19:10-20:00 hrs		
		P1	Can lipid clinic patients be safely discharged? A retrospective audit of consecutive patients discharged from the Newcastle Lipid Clinic in 2020	Muhammad Abbas (Newcastle, UK)	
		P2	Lipoprotein X or LDL-Cholesterol: the diagnostic and treatment conundrum of dual presence	mariana Abdel-Malek (London, UK)	
		P3	Efficacy of Icosapent Ethyl by Burden of Standard Modifiable Cardiovascular Risk Factors: A Secondary Analysis of REDUCE-IT	Rahul Aggarwal (Boston, USA)	
		P4	Familial hypercholesterolaemia with high triglycerides: A diagnostic challenge	Suha Ahmed (Manchester, UK)	
		P5	Case Series on Familial Chylomicronaemia Syndrome (FCS) and Multifactorial Chylomicronaemia Syndrome (MCS) Presenting to a Lipid Clinic in a District General Hospital	Hiruni Amarasekara (Buckinghamshire, UK)	
		P6	An audit of a district general lipid clinic patient cohort with high lipoprotein(a), using the Heart UK consensus statement no. 9	Hiruni Amarasekara (Buckinghamshire, UK)	
		P7	A Cardiometabolic Fellowship Programme to Reduce CVD Risk and Upskill Primary Care Clinicians in South London	Stephanie Atta (London, UK)	
		P8	Expert Consensus on the Management of Hypertriglyceridemia in India: Insights from Nationwide Deliberations	Sarita Bajpai (Mumbai, INDIA)	
		P9	A review of prescribing and monitoring practices of PCSK9 inhibitors and Inclisiran for secondary prevention at St George's hospital (SGH) specialist lipid clinic	Pedro Bandeira (London, UK)	
		P10	Evinacumab – Hammersmith Experience	Lucy Barton (London, UK)	
		P11	Neurodegeneration in Familial Chylomicronaemia Syndrome	Bilal Bashir (Manchester, UK)	
		P12	Unusual responses to PCSK9i therapy in twin sisters with familial hypercholesterolemia	Muhammed-Amin Bax (Chorley, UK)	
		P13	Innovations in Lipid management: The role of inclisiran in achieving LDL-C Reduction. Addressing primary care challenges and cost barriers	Claire Chalwin (London, UK)	
		P14	"Speed Screening" - A pilot study to address lengthy waiting times for Familial Hypercholesterolaemia (FH) Genetic screening	Claire Chalwin (London, UK)	
		P15	High HDL cholesterol; what are the causes?	Tatiana Christmas (London, UK)	
		P16	Points of care: A pilot community cardiovascular disease prevention event utilising point of care testing	Helen Cordy (Cardiff, UK)	
		P17	Have service developments resulted in more children being diagnosed with Familial Hypercholesterolaemia (FH) in Wales?	Carolyn Cude (Cardiff, UK)	

		P18	Refining Lipid-Lowering Strategies: An Audit of Inclisiran Prescribing Compliance with NICE Guidelines in a Cardiology Department.	Marwa Elgizouli (Manchester, UK)	
		P19	Altered Corneal Nerve Morphology and PCSK9 Profiles in People with Type 1 Diabetes: Evidence for Lipid-Mediated Small Fibre Neuropathy	Maryam Ferdousi (Manchester, UK)	
		P20	Development of bi-specific ANGPTL3-DGAT2 siRNA therapies for cardiometabolic disease	Mitchell Geer (Bristol, UK)	
		P21	Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA): Two Patients with Familial Hypercholesterolaemia.	Robert Gingell (Denbighshire, UK)	
		P22	Availability and awareness of Lipoprotein (a) in India – an online review and survey	Arnav Gupta (Mumbai, INDIA)	
		P23	Increasing the identification rate of familial hypercholesterolaemia (FH) in Wales	Kate Haralambos (Cardiff, UK)	
		P24	A survey of the knowledge and confidence in cardiovascular disease risk and management in Health Care Professionals working in Cystic Fibrosis	Lydia Hudson (Manchester, UK)	
		P25	Participant experiences of receiving additional findings for cancer and familial hypercholesterolemia from the 100,000 Genomes Project	Steve Humphries (London, UK)	
		P26	Optimising LDL-C reduction with Inclisiran: Insights from a Retrospective Audit	Ahmad Husain, Michael Habashi (Birmingham, UK)	
		P27	Risk Prediction and Quantification of Cardiovascular Disease Using Machine Learning: Advancing Early Diagnosis with Clinical Insights	Vijay Suryakant Kapse (Manipal, INDIA)	
		P28	Navigating the Complexities of Abetalipoproteinemia: A 12-Year Clinical Journey	Lina Kayali (Nottingham, UK)	
		P29	Withdrawn		
		P30	Cardiovascular risk profile in patients undergoing genetic testing in a Newport Lipid clinic – monogenic Familial Hypercholesterolaemia versus polygenic hypercholesterolaemia	Haidar Mathieson (Cambridge, UK)	
		P31	LIPID PARAMETERS AND ADHERENCE TO ESC GUIDELINES IN PATIENTS WITH ACUTE CORONARY SYNDROME - A SINGLE CENTRE OBSERVATIONAL STUDY	Salik Memon (Birmingham, UK)	
		P32	Hairdressing Salons to improve uptake of NHS Health Checks: BELONG-Study Evaluation	Kritika Mishra (London, UK)	
		P33	Real world efficacy of Inclisiran in LDL cholesterol reduction: A retrospective analysis in a tertiary care setting	Nandana Nair (London, UK)	
		P34	Changes in Lipoprotein(a) Levels in Patients Undergoing Repeat Testing	Nalin Natarajan (London, UK)	
		P35	Appropriateness of Lp(a) Testing in Secondary Care	Nalin Natarajan (London, UK)	
		P36	A retrospective analysis of all patients with familial hypercholesterolaemia in CHFT	Tejashree Nidiginti (Huddersfield, UK)	
		P37	Birmingham and Solihull Integrated Care System's Collaborative Approach to Injectable Lipid-Lowering Therapy: A Patient Overview	Antonio Ochoa-Ferraro (Birmingham, UK)	
		P38	Statin Intolerance: A Review of Diagnosis and Rechallenging Therapy	Shaima Osman ((Manchester, UK)	
		P39	Higher mean HbA1c levels in patients with increased APOB/APOA1 ratios in a multi-ethnic lipid clinic cohort	Pritpal Singh Padam (London, UK)	
		P40	How Impactful is the Lipid Clinic?	Stewart Pattman (Northumbria, UK)	

		P ₄₁	Lipoprotein (a) Concentrations in Children and Young People with Heterozygous Familial Hypercholesterolaemia	Lorraine Priestley-Barnham (Harefield, UK)	
		P ₄₂	Lipoprotein(a) in Children and Young People with Heterozygous Familial Hypercholesterolemia: Ancestry and Cardiovascular Risk	Lorraine Priestley-Barnham (Harefield, UK)	
		P ₄₃	Beyond the Score: Evaluating Coronary Risk in Young Adults with Familial Hypercholesterolaemia	Lorraine Priestley-Barnham (Harefield, UK)	
		P ₄₄	Lipoprotein(a) review of practice: A shift in perspective and an unmet need	Gary Roulston (Belfast, N IRELAND)	
		P ₄₅	Effectiveness of measuring lipoprotein (a) concentration in management of dyslipidemia patients to reduce cardiovascular events in high-risk groups	Md Sadman Sakib Saadi (Lancashire, UK)	
		P ₄₆	Review of 'Advise and Refer' requests to the Lipid Clinic at Queen Elizabeth Hospital, Birmingham for management of hyperlipidaemia	Ritesh Sah (Birmingham, UK)	
		P ₄₇	The effects of Inclisiran on LDL cholesterol levels and Lipoprotein (a) levels in a lipid clinic in South Tyneside and Sunderland NHS Foundation Trust	Gabrielle Stokes (Sunderland, UK)	
		P ₄₈	An innovative cardio-renal-metabolic secondary prevention multidisciplinary service leads to improved risk factor optimisation for people treated for ischaemic stroke compared to existing models of care	Su Ann Tee (Gateshead, UK)	
		P ₄₉	Regional Survey of Lipid Services in the North East and North Cumbria (NENC)	Su Ann Tee (Gateshead, UK)	
		P ₅₀	POC LIPID PROFILE MEASUREMENT AS AN ALTERNATIVE TO LAB PROFILE IN PATIENTS WITH ACUTE ISCHAEMIC STROKE	Aravind Udayan (London, UK)	
		P ₅₁	Evkeeza; Half the cholesterol, double the hope with a new treatment	Julie Wagg (London, UK)	